Slides
Page 1
5 NOVEMBER 2026 First nine months of 2026 FINANCIAL RESULTS
Page 2
DISCLAIMER 2 This Presentation has been prepared by Laboratorios Farmacéuticos ROVI, S.A. (the “Company”) and comprises the slides for a presentation concerning the Company and its subsidiaries (the “Group”). For the purposes of this disclaimer, “Presentation” means this document, its contents or any part of it, any oral presentation, any question or answer session and any written or oral material discussed or distributed during the Presentation meeting or otherwise in connection with it. This Presentation does not constitute or form part of, and should not be construed as, any offer to sell or issue or invitation to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for any securities of the Company, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. The information contained in this Presentation does not purport to be comprehensive. None of the Company, its respective subsidiaries or affiliates, or its or their respective directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to the truth, fullness, accuracy or completeness of the information in this Presentation (or whether any information has been omitted from the Presentation) or any other information relating to the Group, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this Presentation or its contents or otherwise arising in connection therewith. Each of such persons accordingly disclaims all and any liability whatsoever, whether arising in tort, contract or otherwise in respect of this Presentation or any such information. The information in this Presentation may include forward-looking statements, which are based on current expectations, projections and assumptions about future events. These forward-looking statements as well as those included in any other information discussed in the Presentation are subject to known or unknown risks, uncertainties and assumptions about the Group and its investments, including, among other things, the development of its business, its growth plan, trends in its operating industry, its future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur and actual results, performance or achievements may materially differ from any future results, performance or achievements that may be expressed or implied in this Presentation. No representation or warranty is made that any forward-looking statement will come to pass. Forward-looking statements speak as of the date of this Presentation and no one undertakes to publicly update or revise any such forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, undue reliance should not be placed on any forward-looking statement contained in this Presentation. To the extent available, the industry, market and competitive position data contained in this Presentation come from official or third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company reasonably believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry, market and competitive position data contained in this Presentation come from the Company’s own internal research and estimates based on the knowledge and experience of the Company’s management in the markets in which the Group operates. While the Company reasonably believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change. Accordingly, undue reliance should not be placed on any of the industry, market or competitive position data contained in this Presentation. This Presentation also includes certain alternative performance measures ("APMs") that have not been prepared under IFRS-EU and have not been reviewed or audited by the Company’s auditors nor by any independent expert. Moreover, the way the Group defines and calculates these measures may differ to the way similar measures are calculated by other companies. Accordingly, they may not be comparable. Certain financial and statistical information contained in this Presentation is subject to rounding adjustments. Accordingly, any discrepancies between the totals and the sums of the amounts listed are due to rounding. Certain financial information and operating data relating to the Company contained in this Presentation has not been audited and in some cases is based on management information and estimates, and is subject to change. No reliance may or should be placed by any person for any purposes whatsoever on this Presentation, or on its completeness, accuracy or fairness. The information in this Presentation is in summary draft form for discussion purposes only. The information and opinions contained in this Presentation are provided as at the date of the Presentation and are subject to verification, correction, completion and change without notice. In giving this Presentation, none of the Company, its subsidiaries or affiliates, or its or their respective directors, officers, employees, advisers or agents, undertakes any obligation to amend, correct or update this Presentation or to provide the recipient with access to any additional information that may arise in connection with it.
Page 3
• The acquisition was completed on 1 April 2026. As a result of the provisional purchase price allocation process, a bargain purchase gain (badwill) of €62.4 Mn was recognized and recorded as non- recurring income in the consolidated income statement, subject to potential adjustments during the 12-month measurement period • Total revenue: +19% YoY to €633.7 Mn • CDMO performed strongly: +45% YoY to €263.9 Mn • Specialty pharmaceutical business: +1% YoY: – Okedi® continued its strong momentum: +29% YoY to €53.0 Mn – Heparin franchise: -5% YoY due to high inventory levels accumulated by partners • Gross profit: +26% YoY to €443.7 Mn • Gross margin improvement driven by: – Strong performance of the CDMO business – Higher Okedi® contribution – Lower LMWH raw material prices – Revenue from CDTI R&D aid (LAISOLID project) 9M 2026 financial results - highlights 3 To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 32-36) of the press release on the financial results for the first nine months of 2026. Said document is available on ROVI’s website and may be accessed on the following link: https://www.rovi.es/en/shareholders-investors/financial-business-information. Key milestones €610.2 Mn Operating revenue 16% vs 9M 2025 72.7% Gross margin +5.7 pp vs 9M 2025 2026 Outlook update 37.1% EBITDA Margin +8.7 pp vs 9M 2025 • EBITDA: +52% YoY to €226.6 Mn • EBITDA excluding badwill: +10% YoY to €164.3 Mn, with a 26.9% margin • Operating revenue guidance upgraded to mid-to-high single-digit growth vs. 2025, from the previously expected low-to-mid single-digit growth
Page 4
First nine months of 2026 Business Performance
Page 5
Prescription-based pharmaceutical products: -1% YoY Performance of the specialty pharmaceutical business Specialty pharmaceutical business: +1% supported by Okedi® (+29%) €Mn 343.3 (5.8) (4.1) 12.0 1.2 (5.1) 0.01 4.5 346.1 9M 2025 Specialty pharma revenue Enoxaparin biosimilar Bemiparin Okedi® Neparvis® Other productsDiscounts to the NHS Contrast agents and other hospital products 9M 2026 Specialty pharma revenue 5
Page 6
• Improvement expected in Q4, supported by orders from partners • 2026 outlook: low-single- digit growth vs. 2025 ROVI, a leading player in the global LMWH market Bemiparin 70.8 66.7 112.8 107.0 183.6 173.7 Bemiparin Enoxaparin biosimilar 9M 2025 9M 2026 0102030405060708090100110120130140150160170180190200 6 (1) Heparin franchise includes low molecular weight heparins and other heparins. Other heparins are reported in the "Contrast agents and other hospital products" line. 299.3 297.6 9M 2025 9M 2026 189.8 180.9 9M 2025 9M 2026 -5% -6% Heparins accounted for 30% of operating revenue in 9M 2026 -1% -5% -5% €Mn€Mn €Mn Enoxaparin biosimilar Low molecular weight heparin (LMWH) sales -5% vs 9M 2025 Prescription-based sales -1% vs 9M 2025 Heparin franchise(1) -5% vs 9M 2025 • Approved in 26 countries in Europe and 33 in the rest of the world • Directly marketed in Germany, UK, Italy, Austria, Portugal and Spain • Expansion in other markets through out- licensing agreements with international partners: 82 territories signed 2026 LMWH outlook: ROVI maintains its guidance for a m i d s i n g l e ‑ d i g i t d e c l i n e ( v s . a h i g h - s i n g l e - d i g i t d e c l i n e previously expected) reflecting a more favorable performance than initially expected despite partner inventory adjustments and pricing pressure • Over 70 years of expertise in heparin- based drug development • Only 2nd generation LMWH; clinical differentiated from other competitors • Commercial presence in +60 countries
Page 7
Strong commercial momentum Okedi®: a key growth driver for the specialty pharmaceutical business in 9M 2026 7 +29% Differentiated clinical value Peak sales 2.0 14.4 28.8 56.7 41.0 53.0 2022 2023 2024 2025 9M 2025 9M 2026 Okedi® sales performance • Continued growth across key European markets • Q3 2026: +35% YoY and +13% vs. Q2 2026 • €100–200 Mn €Mn • Rapid and sustained efficacy, with rapid onset of action from Day 1, with no oral supplementation or loading dose required • Improved patient functioning since first injection, accompanied by a favorable tolerability profile • Low rates of relapse, rehospitalization and discontinuation due to treatment-emergent adverse events (TEAEs)
Page 8
Value added CDMO services 8 181.7 263.9 9M 2025 9M 2026 +45% ROIS Phoenix (USA) High-potent vial manufacture, fill&Lyo and packaging ROIS Julián Camarillo (Madrid) Fill & finish of PFS(1) and cartridges ROIS San Sebastián de los Reyes Fill & finish of PFS(1), cartridges and vials ROIS Alcalá de Henares Center of excellence for injectable packaging and assembly ROIS Granada API Biologics manufacturing site Our global manufacturing network Strong performance of the CDMO business (1) PFS stands for "Prefilled syringe"- €Mn
Page 9
9 ISM® Platform opens up new avenues of growth for ROVI Overview Key Company Highlights of ISM® Platform • Internally-developed and patented innovative drug-release technology, ISM®(1), which allows for the sustained release of compounds administered by injection • Based on two separate syringes containing, respectively, (i) the drug and polymer (solid state) and (ii) the solvent (liquid state) • Potential wide applicability of ISM® technology to new chronic therapeutic areas, including psychiatry and oncology • 505(b)(2) path of approval for candidates leveraging ISM® technology Key Milestones Predictability Pop PK(3) model & simulations already validated for Risperidone-ISM® in Phase I & II Clinical Program Expected high success rate in Phase III in new developments Usability Improved stability No cold chain needed Flexibility Selecting the most convenient posology depending on clinical needs From 1 to 12 months administration Improved Clinical Management Long-acting injection (1-12 months) plasma therapeutic levels from day 1 Rapid onset & sustained clinical effect Vertical Integration Technological barriers (e.g. power filling) Strong IP Manufacturing capabilities Protected technology Fully integrated manufacturing plants 1 2 3 4 5 9 (1) ISM® stands for In Situ Microimplants. (2) Superior Inhibition of Estrogens (3) PK stands for pharmacokinetic Product Potential Indication Current Situation Key Milestones Risperidone ISM®, monthly Schizophrenia Approved Marketed in Europe, and in Australia & Taiwan Letrozole ISM®, annual Breast Cancer Clinical development on hold Phase I: Superior oestrogen suppression vs Femara® Letrozole SIE(2), quarterly Breast Cancer Completion of Phase I Phase I: positive readout confirms superior estrogen suppression vs Femara®. Phase III started in Q3 2026 Risperidone ISM®, quarterly Schizophrenia Completion of Phase I Phase I: positive readout allows progression to Phase III clinical trial Concentrated on improving posology for already approved compounds, which benefits risk / reward profile Multiple FDA / GMP approved facilities to support the platform
Page 10
First nine months of 2026 Financial Performance
Page 11
(*) Note: "Other operating revenue” includes service activities that are not material to the Group. In 9M 2025 results release, this amount was included within the “Contrast agents & hospital products & others” line. To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 32-36) of the press release on the financial results for the first nine months of 2026. Said document is available on ROVI’s website and may be accessed on the following link: https://www.rovi.es/en/shareholders-investors/financial-business-information. Specialty pharmaceutical business 525.1 (1.7) 4.5 82.2 0.0 610.2 9M 2025 operating revenue Prescription productsContrast agents & hospital products & others CDMO Other operating revenue(*) 9M 2026 operating revenue 11 €Mn 11 Revenue growth mainly driven by the CDMO business 9M 2026 operating revenue variation: +16%
Page 12
352.1 443.7 67.1% 72.7% Gross profit Gross margin 9M 2025 9M 2026 0 200 400 50% Gross profit and gross margin 12 +5.7 pp €Mn To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 32-36) of the press release on the financial results for the first nine months of 2026. Said document is available on ROVI’s website and may be accessed on the following link: https://www.rovi.es/en/shareholders-investors/financial-business-information. Gross margin uplift from R&D aid, the increase in CDMO activity, Okedi® and lower LMWH raw material prices Gross profit increased by 26% to €443.7 Mn in 9M 2026. Gross margin rose by 5.7 pp to 72.7% in 9M 2026, partly driven by CDTI R&D aid. Excluding “Other income”, gross margin increased by 3.5 pp to 68.9%, mainly due to increased CDMO activity, higher Okedi® contribution and lower LMWH raw material costs. Gross profit impacts +26%
Page 13
R&D expenses increased by 136% to €58.4 Mn in 9M 2026. They were mainly related to the preparation and start of the phase III clinical trial of Letrozole SIE, with patient recruitment beginning in the third quarter of 2026. SG&A with continued R&D commitment SG&A expenses 177.9 221.2 33.9% 36.3% SG&A SG&A/Operating revenue 9M 2025 9M 2026 0 250 0% 10% 20%30% 40% 50% R&D expenses 13 €Mn €Mn (1) Source: https://www.boe.es/eli/es/res/2025/02/06/(1) To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 32-36) of the press release on the financial results for the first nine months of 2026. Said document is available on ROVI’s website and may be accessed on the following link: https://www.rovi.es/en/shareholders-investors/financial-business-information. +24% 24.7 58.4 9M 2025 9M 2026 0 10 20 30 40 50 60 70 +136% SG&A increased 24% to €221.2 Mn in 9M 2026, driven by: – “Employee benefit expenses (excl. R&D)”: + 25% YoY, due to (i) the addition of ROIS Phoenix employees, (ii) a 3% wage increase, (iii) the hiring of new CDMO personnel, and (iv) non-recurring expenses related to a tax inspection; and – “Other operating expenses (excl. R&D)”: + 23% YoY driven by (i) the consolidation of ROIS Phoenix, (ii) a lower comparison base in 2025 following the temporary shutdown of the Madrid facility, and (iii) non- recurring expenses (write-off of non-operating assets and strategic projects). ROIS Phoenix expenses represented ~12% of 9M 2026 SG&A expenses. 2026 SG&A Outlook : ROVI maintains its guidance for mid- to high- s i n g l e ‑ d i g i t g r o w t h v s . 2 0 2 5 , e x c l u d i n g R O I S P h o e n i x .
Page 14
149.5 226.6 28.5% 37.1% EBITDA EBITDA Margin 9M 2025 9M 2026 0 250 0% EBITDA EBIT Net Profit EBITDA, EBIT & Net Profit analysis 97.7 162.8 9M 2025 9M 2026 0 200 149.5 91.6 (43.3) 62.4 (33.7) 0.1 226.6 EBITDA 9M 2025 Gross profit SG&A Gain on bargain purchase R&D Share of profit of a joint venture EBITDA 9M 2026 0 0.2 0.4 €Mn€Mn €Mn€Mn 14 To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 32-36) of the press release on the financial results for the first nine months of 2026. Said document is available on ROVI’s website and may be accessed on the following link: https://www.rovi.es/en/shareholders-investors/financial-business-information. 127.3 198.7 24.2% 32.6% EBIT EBIT Margin 9M 2025 9M 2026 0 120 240 0% 10% 20% 30% 40% +67% +56%+52%
Page 15
Capital expenditure and Cash Flow 15 28.3% 1.1% 22.8%47.8% To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 20-22 and Appendix 2 (pages 32-36) of the press release on the financial results for the first nine months of 2026. Said document is available on ROVI’s website and may be accessed on the following link: https://www.rovi.es/en/shareholders-investors/financial-business-information. 9M 2026 €50.3 Mn (21.9) 111.0 (50.3) (23.0) (49.1) (0.5) 5.8 (27.9) Net debt (-)/cash (+) FY 2025 Net cash from operating activities Capex Other cash flows from investing activities Dividends paidTreasury Shares Other Net debt (-)/cash (+) 9M 2026CAPEX Evolution +31% vs 9M 2025 Cash flow evolution New filling lines and operations expansion Glicopepton ISM® Industrialisation Main investments Glicopepton ISM® Industrialisation New filling lines and operations expansion Maintenance capex
Page 16
ROVI's General Shareholders' Meeting approved the distribution of a dividend of €0.9594 per share entitled to receive it, charged to the 2025 profit and distributable reserves. This dividend was paid on 15 July 2026. Debt overview Debt breakdown by source (%) Debt maturities Total debt €100.9 Mn 7.3 28.9 27.2 21.1 16.5 2026 2027 2028 2029 2030 + 0.0 10.0 20.0 30.0 40.0 16 To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 19-20 and Appendix 2 (pages 32-36) of the press release on the financial results for the first nine months of 2026. Said document is available on ROVI’s website and may be accessed on the following link: https://www.rovi.es/en/shareholders-investors/financial-business-information. €Mn 11.0% 9.9% 79.1% Bank borrowings Financial liabilities for leases Debt with public administration Net debt of €27.9 Mn as of 30 September 2026 vs net debt of €21.9 Mn as of 31 December 2025
Page 17
2027 Outlook Strong R&D investment, with two Phase III clinical trials: Letrozole SIE initiated in Q3 2026 and Risperidone QUAR expected in Q4 2026 Sustained growth of the specialty pharmaceutical business, driven by Okedi® 2027 guidance to be provided with FY 2026 results, expected in February 2027 Value creation from the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) Strong momentum in CDMO business: consistent and focused execution 17 Outlook and closing remarks Vertical integration of the heparin division to enhance cost efficiency and improve competitiveness Closing remarks
Page 18
In addition to the financial information prepared in accordance with International Financial Reporting Standards (“IFRSs”) taken from our financial statements, this document includes certain alternative performance measures (“APMs”) as defined in the ESMA (European Securities and Markets Authority) Guidelines on Alternative Performance Measures of 5 October, 2015 (ESMA/2015/1415), as well as some non-IFRS financial indicators. The financial measures contained in this document that are considered APMs or non-IFRS financial indicators have been prepared on the basis of the ROVI Group’s financial information but are not defined or set out in detail within the framework of the applicable financial information and have not been audited or reviewed by ROVI's auditors. These APMs are considered figures that have been adjusted in respect of those that are presented in accordance with the International Financial Reporting Standards endorsed by the European Union (IFRS-EU), which form the applicable accounting framework for the consolidated financial statements of the ROVI Group. Therefore, the reader should consider them to complement the latter but not to replace them. ROVI uses these APMs and non-IFRS financial indicators to plan, oversee and assess its performance. ROVI considers the APMs and non- IFRS financial indicators to be useful to allow the management team and investors to compare the past or future financial performance, the financial situation and the cash flows. Notwithstanding, these APMs and non-IFRS financial indicators are considered complementary and are not intended to replace IFRS measures. Furthermore, other companies, including some in ROVI's sector, may calculate such measures differently, which reduces their usefulness for comparative purposes. To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used by ROVI, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on Appendix 2 (pages 32-36) of the press release on the financial results for the first nine months of 2026. Said document is available on ROVI’s website and may be accessed on the following link: (https://www.rovi.es/en/shareholders-investors/financial-business-information). Alternative performance measures 18
Page 19
Juan López-Belmonte Chairman and Chief Executive Officer www.rovi.es Javier López-Belmonte Deputy Chairman and Chief Financial Officer www.rovi.es Marta Campos Head of Finance mcampos@rovi.es www.rovi.es Beatriz de Zavala Investor Relations Analyst bdezavala@rovi.es www.rovi.es Victoria López-Belmonte Investor Relations Analyst vlopez-belmonte@rovi.es www.rovi.es For further information, please contact: